HealthTree Logo
search more_vert
close
person Sign In / Create Account
What are the Treatment Options for CLL?
Posted: Jul 21, 2023
What are the Treatment Options for CLL? image

CLL specialists Drs. Alvaro Alencar and Matthew Butler share what the current treatment options are for CLL. Watch their interview below: 

Current non-chemo CLL treatments can be divided into two groups: fixed-duration and continual-duration therapies

Fixed-duration therapies 

Fixed-duration therapies like venetoclax (venclexta) paired with an antibody medicine like obinutuzumab (gazyva) or rituximab (rituxan) are administered over the course of 1 year for previously untreated CLL and for up to 2 years for previously treated CLL. Patients may prefer a fixed duration therapy as it is not administered long-term and treatment has an end date. 

Venetoclax in combination with an antibody therapy has shown to be effective for the majority of CLL patients in reducing the disease to an undetectable state and helping the patient remain in remission for up to 5 years. Once the disease resurfaces to a point that qualifies for treatment (as the disease is typically slow growing, this may be several more years even if the disease is present), another round of treatment would be administered to achieve an additional remission (reduced or no signs/symptoms of the disease present).  

Continual-duration therapies 

Continual duration therapies include BTK inhibitors (acalabrutinib [calquence] and zanubrutinib [brukinsa]). These medicines taken in the form of a tablet by mouth are administered long-term until the disease progresses and the patient no longer responds to treatment.

Patients may prefer to take a BTK inhibitor pill long-term instead of a fixed-duration therapy like venetoclax for reasons such as the antibody portion of the venetoclax treatment combination is administered by IV for 9 infusions, each infusion lasting about 90 minutes (spread out over 6 months). The infusion time done in a clinic setting may be seen as inconvenient. 

Patients should discuss their treatment preferences with a CLL specialist. Need help to find a CLL specialist? Visit HealthTree's CLL specialist directory here

HealthTree's CLL Specialist Directory

The author Megan Heaps

about the author
Megan Heaps

 

Megan joined HealthTree in 2022. As a writer and the daughter of a blood cancer patient, she is dedicated to helping patients and their caregivers understand the various aspects of their disease. This understanding enables them to better advocate for themselves and improve their treatment outcomes. In her spare time, she enjoys spending time with her family, sewing, and cooking.

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube